Vaxcyte, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Vaxcyte, Inc. held its Annual Meeting of Stockholders on June 15, 2026, to vote on three key proposals. First, stockholders re-elected three Class III directors—Olivier Brandicourt, M.D., Halley Gilbert, J.D., and Grant Pickering, M.B.A.—to serve until the 2029 Annual Meeting. Second, the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with an overwhelming majority of over 137 million votes in favor. Finally, stockholders approved, on a non-binding advisory basis, the compensation of the company's named executive officers. All proposals passed according to the voting results disclosed in the filing. No new clinical trial data or corporate strategy shifts were announced during this meeting. The report was signed by Andrew Guggenhime, President and Chief Financial Officer, on June 16, 2026.